Back to Search
Start Over
[First-line treatment of hypercholesterolemia : start with statin monotherapy or ezetimibe-statin combination ?]
- Source :
-
Revue medicale de Liege [Rev Med Liege] 2024 Apr; Vol. 79 (4), pp. 202-207. - Publication Year :
- 2024
-
Abstract
- Hypercholesterolemia, especially LDL-C («Low-Density-Lipoprotein - Cholesterol»), is a major cardiovascular risk factor, especially for coronary artery disease. Patients at high or very high cardiovascular risk should reach LDL concentrations as low as possible («the lower, the better»), with a reduction of at least 50 % from baseline levels according to the most recent guidelines, especially those in secondary prevention. An ezetimibe-statin combination most often allows to reach this goal thanks to a complementary action. The objectives of this article are to remind the dual actions of these two medications, to summarize the clinical evidence showing not only a remarkable cholesterol-lowering effect but also a reduction in cardiovascular events in both controlled trials and observational real-life studies, to specify the positioning of this combined oral therapy in the last international guidelines and to mention pharmaceutical specialties that combine ezetimibe with a statin available for the practitioner.
Details
- Language :
- French
- ISSN :
- 0370-629X
- Volume :
- 79
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Revue medicale de Liege
- Accession number :
- 38602206